{"id":"qm1114-dp","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Skin irritation"}]},"_chembl":{"chemblId":"CHEMBL5776166","moleculeType":null,"molecularWeight":"557.40"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by modulating the immune response and reducing inflammation in the skin, which helps to alleviate symptoms of acne and other inflammatory skin conditions.","oneSentence":"QM1114-DP is a topical treatment that targets the inflammatory pathways in the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:04.932Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT05146999","phase":"PHASE3","title":"Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2022-05-09","conditions":"Glabellar Frown Lines","enrollment":132},{"nctId":"NCT05148000","phase":"PHASE3","title":"Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2023-01-23","conditions":"Glabellar Frown Lines, Canthal Lines","enrollment":25},{"nctId":"NCT05463965","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2022-07-29","conditions":"Moderate to Severe Glabellar Lines","enrollment":605},{"nctId":"NCT04247074","phase":"PHASE3","title":"Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-02-10","conditions":"Glabellar Frown Lines (GL), Lateral Canthal Lines (LCL)","enrollment":413},{"nctId":"NCT04249583","phase":"PHASE3","title":"Treatment of Moderate to Severe Glabellar Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-02-10","conditions":"Glabellar Frown Lines","enrollment":300},{"nctId":"NCT04225260","phase":"PHASE3","title":"Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-01-27","conditions":"Glabellar Lines, Lateral Canthal Lines","enrollment":902},{"nctId":"NCT04249687","phase":"PHASE3","title":"Treatment of Moderate to Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2020-02-10","conditions":"Lateral Canthal Lines","enrollment":303}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"QM1114-DP","genericName":"QM1114-DP","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Biologic","firstApprovalDate":"","aiSummary":"QM1114-DP is a topical treatment that targets the inflammatory pathways in the skin. Used for Acne vulgaris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}